To characterize further differences in responsiveness between TP53wt and TP53mut patient-derived cells, AML CD34+ TP53wt cells (n=5) or TP53mut cells (n=4) were treated with HCQ, and p53-dependent transcriptional target gene expression patterns were analyzed. This evidence concerns the gene TP53 and acute myeloid leukemia.